How a Peninsula biotech turned its psoriasis drugs into a $2.4 billion acquisition


Small-molecule drugs supposedly are on the outs, but Lilly was willing to up its bid to nab two drugs targeting psoriasis.

Previous Auction date set for four former United-Lane Furniture sites in Triad and Mississippi
Next Labcorp spinoff Fortrea launches as $3B public company with 19K employees in Durham